(Q34155231)

31 July 2017

1 reference

title

Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. (English)

1 reference

31 July 2017

0 references

Brian Cooper

1

1 reference

31 July 2017

Lisa DeTora

series ordinal

2

1 reference

31 July 2017

Jeffrey Stoddard

series ordinal

3

1 reference

31 July 2017

1 January 2011

1 reference

Expert Review of Vaccines

31 July 2017

1 reference

31 July 2017

10

1 reference

31 July 2017

1

1 reference

31 July 2017

21-33

1 reference

31 July 2017

Meningococcal disease

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

A review of vaccine research and development: meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Advances in the development of vaccines against Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Clinical practice. Prevention of meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Epidemiological profile of meningococcal disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Isolation and characterization of Neisseria meningitidis in the vaccine era. Who needs what and when?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

2010 FIFA world cup South Africa: travel health issues and new options for protection against meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Complications and sequelae of meningococcal disease in Quebec, Canada, 1990-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Case fatality rates for meningococcal disease in an English population, 1963-98: database study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Sequelae due to bacterial meningitis among African children: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Cigarette smoking and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Risk factors for invasive meningococcal disease in southern Queensland, 2000-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Fetal growth, maternal prenatal smoking, and risk of invasive meningococcal disease: a nationwide case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Parental smoking, socioeconomic factors, and risk of invasive meningococcal disease in children: a population based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Influenza and meningococcal disease: lessons for travellers and government from 2 epidemic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Meningococcal vaccines: a neglected topic in travel medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Meningococcal disease and prevention at the Hajj.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Detection and response to a meningococcal disease outbreak following a youth football tournament with teams from four European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Global epidemiology of meningococcal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Invasive meningococcal disease epidemiology and control measures: a framework for evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Modern trends in mortality from meningococcal disease in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Serogroup Y meningococcal disease, Colombia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Clonal spread of serogroup W135 meningococcal disease in Turkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Epidemiology and meningococcal serogroup distribution in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Cluster of serogroup W135 meningococci, southeastern Florida, 2008-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Meningococcal disease among United States military service members in relation to routine uses of vaccines with different serogroup-specific components, 1964-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Prevalence and antimicrobial resistance pattern of bacterial meningitis in Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Vaccines for prevention of meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Evidence for capsule switching between carried and disease-causing Neisseria meningitidis strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Molecular surveillance of Neisseria meningitidis capsular switching in Portugal, 2002-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Genetic study of capsular switching between Neisseria meningitidis sequence type 7 serogroup A and C strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Capsule switching of Neisseria meningitidis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Quadrivalent meningococcal conjugate vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Conquering the meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

A universal vaccine for serogroup B meningococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Vaccinology in the genome era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Decline of Childhood Haemophilus influenzae Type b (Hib) Disease in the Hib Vaccine Era

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Meningococcal disease: risk for international travellers and vaccine strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Meningococcal surrogates of protection--serum bactericidal antibody activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.10.147

21 January 2018

Identifiers

DOI

10.1586/ERV.10.147

1 reference

release_garpwjkbr5e25c5i4fm2thhiia

31 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/garpwjkbr5e25c5i4fm2thhiia

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference